Literature DB >> 35316465

Implementation of Cardiometabolic Centers and Training Programs.

Mohamad B Taha1, Neha Rao2, Muthiah Vaduganathan3, Miguel Cainzos-Achirica1,4, Khurram Nasir1,4, Kershaw V Patel5.   

Abstract

PURPOSE OF REVIEW: Type 2 diabetes is frequently accompanied by obesity, nonalcoholic fatty liver disease, chronic kidney disease, and cardiovascular disease, which collectively contribute to the high burden of cardiometabolic disease. This review discusses cardiometabolic disease management, strategies to implement cardiometabolic centers to deliver care, and dedicated programs to train the next generation of cardiometabolic experts. RECENT
FINDINGS: Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist have demonstrated beneficial effects across cardiometabolic conditions. However, utilization of effective pharmacotherapies is low in clinical practice, in part due to clinical inertia and traditional sharp delineation in clinical responsibilities of specialists. Multidisciplinary clinics and population-health models can provide comprehensive care but require investment in physical and information technology infrastructure as well as in training and accreditation. Post-internal medicine residency cardiometabolic health training programs have been proposed. Implementing cardiometabolic centers in health systems involves reshaping current practices. Training programs focused on cardiometabolic health are needed to address the growing burden of disease and specific training needs in this ever-expanding area.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiometabolic disease; Cardiovascular disease; Care delivery models; Diabetes; Medical training

Mesh:

Year:  2022        PMID: 35316465     DOI: 10.1007/s11892-022-01459-y

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  50 in total

1.  Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.

Authors:  Aidin Rawshani; Araz Rawshani; Stefan Franzén; Björn Eliasson; Ann-Marie Svensson; Mervete Miftaraj; Darren K McGuire; Naveed Sattar; Annika Rosengren; Soffia Gudbjörnsdottir
Journal:  N Engl J Med       Date:  2017-04-13       Impact factor: 91.245

2.  Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease.

Authors:  Suzanne V Arnold; James A de Lemos; Robert S Rosenson; Christie M Ballantyne; Yuyin Liu; Katherine E Mues; Shushama Alam; Mary Elliott-Davey; Deepak L Bhatt; Christopher P Cannon; Mikhail Kosiborod
Journal:  Circulation       Date:  2019-06-07       Impact factor: 29.690

3.  Resurgence in Diabetes-Related Complications.

Authors:  Edward W Gregg; Israel Hora; Stephen R Benoit
Journal:  JAMA       Date:  2019-05-21       Impact factor: 56.272

4.  Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Aidin Rawshani; Araz Rawshani; Stefan Franzén; Naveed Sattar; Björn Eliasson; Ann-Marie Svensson; Björn Zethelius; Mervete Miftaraj; Darren K McGuire; Annika Rosengren; Soffia Gudbjörnsdottir
Journal:  N Engl J Med       Date:  2018-08-16       Impact factor: 91.245

5.  Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.

Authors:  Christian A Schneider; Ele Ferrannini; Ralph Defronzo; Guntram Schernthaner; John Yates; Erland Erdmann
Journal:  J Am Soc Nephrol       Date:  2007-12-05       Impact factor: 10.121

6.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

7.  Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.

Authors:  Muthiah Vaduganathan; Ravi B Patel; Avinainder Singh; Cian P McCarthy; Arman Qamar; James L Januzzi; Benjamin M Scirica; Javed Butler; Christopher P Cannon; Deepak L Bhatt
Journal:  J Am Coll Cardiol       Date:  2019-04-02       Impact factor: 24.094

8.  Long-term follow-up of intensive glycaemic control in type 2 diabetes.

Authors:  Kershaw V Patel; Darren K McGuire
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

9.  Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.

Authors:  Darren K McGuire; Weichung J Shih; Francesco Cosentino; Bernard Charbonnel; David Z I Cherney; Samuel Dagogo-Jack; Richard Pratley; Michelle Greenberg; Shuai Wang; Susan Huyck; Ira Gantz; Steven G Terra; Urszula Masiukiewicz; Christopher P Cannon
Journal:  JAMA Cardiol       Date:  2021-02-01       Impact factor: 14.676

10.  Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes.

Authors:  Michael Fang; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2021-01-08       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.